x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Derms and Conditions

Hear from the leading dermatologists and experts as they discuss the hottest topics in dermatology. Tune in for clinical practice tips and treatment pearls you can implement quickly and efficiently into your busy practices!

health & fitness medicine

All Episodes

23:36

Whom Do You Trust? Learn More About Trusts & Wills

Derms and Conditions ·

2025/04/10

In this episode of Derms and Conditions, Dr James Q. Del Rosso shifts gears from clinicaldermatology to something equally important but rarely discussed—legal and financial planning. He’s joined by his longtime friend and dermatopathologist, Dr Clay Cockerell, who also happens to be a licensed attorney with a passion for educating physicians about estate planning. Dr Cockerell breaks down the fundamentals of trusts, wills, and malpractice insurance in plain language, highlighting why every

en

27:00

Atopic Dermatitis in Kids: Non-Steroidal Advances...

Derms and Conditions ·

2025/03/28

In this episode of Derms and Conditions, Dr James Q. Del Rosso welcomes back hislongtime friend and pediatric dermatology expert, Dr Lisa Swanson. Together, they explore the rapidly evolving treatment landscape for pediatric atopic dermatitis, with a focus on newly approved non-steroidal topical therapies. Dr Swanson shares her insights on tapinarof 1% cream, now FDA-approved for patients as young as two years old, and topical roflumilast 0.15% cream, approved down to age six. The duo discusses

en

20:21

Poster Power: A Review of Selected Highlights from WCH25

Derms and Conditions ·

2025/03/13

In this episode of Derms and Conditions, host Dr James Q. Del Rosso returns from the 2025Winter Clinical Dermatology Conference – Miami® with a deep dive into some of the standout posters presented at the meeting. Dr Del Rosso begins the review with new insights on topical clascoterone 1% cream and its impact on the skin barrier, tolerability, and sebum reduction. He explores recent studies showing that clascoterone does not compromise the permeability barrier or increase transepidermal water

en

13:09

Highlights from Winter Clinical Hawaii 2025: Recorded...

Derms and Conditions ·

2025/02/27

In this special live episode of Derms and Conditions, recorded at the 2025 Winter Clinical Dermatology Conference - Hawaii®, host Dr James Q. Del Rosso welcomes Dr April Armstrong, chief of dermatology at UCLA, and Dr David Cohen, dermatologist at NYU Langone, to break down the key takeaways from this year’s meeting.The discussion kicks off with chronic hand eczema, a condition that can be difficult to diagnose and treat due to its multiple causes. Dr Cohen highlights emerging data on new

en

25:47

"Don't Sweat It" You Say? With Once A Day, There Is A...

Derms and Conditions ·

2025/02/20

In this episode of Derms and Conditions, host James Q. Del Rosso, DO, welcomes Lawrence Green, MD, clinical professor at George Washington University and practicing dermatologist, to discuss the evolving landscape of hyperhidrosis and the latest FDA-approved therapy, sofpironium bromide gel.Dr Green highlights that an estimated 16 million people in the US experience clinical hyperhidrosis, with axillary hyperhidrosis being the most frequently reported. However, a significant challenge is patient

en

25:15

How to Streamline Study Data to Improve Selection of...

Derms and Conditions ·

2025/02/13

In this episode of Derms and Conditions, host James Del Rosso, DO, welcomes Ron Vender, MD, Associate Clinical Professor of Dermatology at McMaster University, to discuss practical strategies for psoriasis treatment and the management of chronic hand dermatitis.They begin with Dr Vender sharing his 90/70/40 rule, a numeric approach to evaluating biologic efficacy in psoriasis. He explains that across biologic agents, PASI75 responses typically reach 90%, PASI90 responses reach 70%, and PASI100

en

24:45

Dermatology & Social Media: Tips on Engaging with...

Derms and Conditions ·

2025/02/06

In this episode of Derms and Conditions, James Del Rosso, DO, welcomes Dustin Portela, DO, a private practice dermatologist in Boise, ID, and well-known social media presence, to discuss the challenges and responsibilities of dermatologists engaging online while maintaining professional integrity.Dr Portela shares how he unintentionally became an influencer, initially using social media to market his new practice without a budget. His following grew as he provided accurate, engaging, and

en

27:22

Hidradenitis Suppurativa: Can You Move the Needle to...

Derms and Conditions ·

2025/01/23

In this episode of Derms and Conditions, host James Q. Del Rosso, DO, welcomes Michael Payette, MD, a dermatologist in private practice at Central Connecticut Dermatology, to discuss practical approaches to managing hidradenitis suppurativa (HS). Dr Payette shares his experience establishing a dedicated HS clinic and provides insights into addressing diagnostic delays, patient education, and emerging treatments.They begin by discussing the importance of outreach and education to raise awareness of

en

26:37

My Pregnancy Test Is Positive and My Eczema Is Bad!”...

Derms and Conditions ·

2025/01/09

In this episode of Derms and Conditions, host James Q. Del Rosso, DO, welcomes Mona Shahriari, MD, associate director of clinical trials at Central CT Dermatology and assistant clinical professor at Yale University, to discuss the challenges of treating pregnant and breastfeeding patients, particularly those with atopic dermatitis (AD).The conversation addresses a crucial yet often unclear topic for dermatologists: balancing safety and efficacy when managing AD in patients during pregnancy and

en

25:10

Celebrating Episode 100 with the Greatest Hits from...

Derms and Conditions ·

2024/12/19

In this milestone 100th episode of Derms and Conditions, host James Del Rosso, DO, takes listeners on a year-in-review journey through some of the greatest highlights from 2024. This special solo episode reflects on standout conversations with leading dermatologists and previews exciting plans for 2025.Dr Del Rosso revisits key insights from some of the most impactful episodes on this 100th Episode of Derms and Conditions Podcasts: Episode 91 with Dr Joel Gelfand explored psoriasis

en

23:14

Facing The Challenges of Systemic Therapy Selection...

Derms and Conditions ·

2024/12/12

In this episode of Derms and Conditions, host James Q. Del Rosso, DO, is joined by Brad Glick, DO, dermatologist and residency program director at Larkin Health Center in South Florida, to discuss the complexities of selecting systemic therapies for psoriasis. They share insights on navigating the abundance of treatment options, focusing on patient-centric considerations, with an emphasis on the TYK2 inhibitor deucravacitinib.They begin by highlighting how treatment selection often depends more on

en

25:11

Thinking Beyond the Cytokines: Optimizing Management...

Derms and Conditions ·

2024/12/05

In this episode of Derms and Conditions, host James Q. Del Rosso, DO, welcomes E. James Song, MD, Chief Medical Officer at Frontier Dermatology, to explore the nuances of systemic therapy selection for atopic dermatitis (AD) and offer practical guidance on tailoring treatment plans to optimize outcomes for these patients.They begin by discussing the importance of considering patient-specific factors, such as contraindications, access, and age, when selecting among the 3 currently available

en

24:06

Let's Take It From The Top: Emphasis on Psoriasis

Derms and Conditions ·

2024/11/26

In this episode of Derms and Conditions, host James Q. Del Rosso, DO, welcomes Tina Bhutani, MD, CEO and clinical dermatologist at Synergy Dermatology in San Francisco, to explore the evolving role of topical corticosteroids in psoriasis care and their interplay with newer nonsteroidal agents. With the wide array of treatments available today, they highlight the enduring importance of topicals in dermatology practice, even as systemic therapies become increasingly effective.They begin by

en

26:11

A Real-World Discussion of Patch Testing in Atopic...

Derms and Conditions ·

2024/11/21

In this episode of Derms and Conditions, host James Del Rosso, DO, welcomes David Cotter, MD, a dermatologist in clinical practice and assistant clinical professor at the University of Nevada Las Vegas School of Medicine, to discuss the integral role of patch testing in managing atopic dermatitis (AD) and allergic contact dermatitis (ACD), providing practical insights on incorporating patch testing into practice and differentiating between these often-overlapping conditions. They begin with Dr

en

29:39

A Real-World Conversation: Differentiating and...

Derms and Conditions ·

2024/11/14

In this episode of Derms and Conditions, host James Q. Del Rosso, DO, invites Peter Lio, MD, a clinical professor of dermatology at Northwestern University, to explore the complexities of selecting therapies for atopic dermatitis (AD) with a particular focus on the newly approved IL-13 inhibitor, lebrikizumab. With a growing number of treatment options, Dr Lio and Dr Del Rosso examine how these therapies are enhancing patient management in unique ways.The discussion opens with a look at the current

en

27:06

Pediatric Dermatology Research: Doing the Right...

Derms and Conditions ·

2024/11/07

In this episode of Derms and Conditions, host James Q. Del Rosso, DO, welcomes Adelaide Hebert, MD, chief of pediatric dermatology at McGovern School of Medicine and Children’s Memorial Hermann Hospital in Houston, to discuss the intricacies and challenges of pediatric clinical research.They begin by noting that past limitations left clinicians with few FDA-approved treatment options for younger patients, often relying on off-label therapies without robust pediatric data. However, legislative

en

16:19

The Best of Fall Clinical 2024—Live from Las Vegas!

Derms and Conditions ·

2024/10/31

In this special live episode of Derms and Conditions, recorded at the Fall Clinical Dermatology 2024 Meeting, host Dr James Q. Del Rosso welcomes Dr April Armstrong, chief of dermatology at UCLA, to discuss key highlights from the conference. Together, they cover the latest in psoriasis treatments, promising developments for vitiligo, advances in hidradenitis suppurativa, and much more.The discussion kicks off with psoriasis, where exciting progress in oral TYK2, IL-23, and IL-17A inhibitors is

en

23:54

It’s Always Good to Have Options: Expanding the Menu...

Derms and Conditions ·

2024/10/17

In this episode of Derms and Conditions, host James Q. Del Rosso, DO, welcomes Mona Shahriari, MD, associate director of clinical trials at Central CT Dermatology and assistant clinical professor at Yale University, to discuss the recent FDA approval of lebrikizumab, approved for atopic dermatitis (AD) in patients 12 years of age and up who have failed topical treatments like corticosteroids or calcineurin inhibitors, and its potential impact on treatment strategies.They begin by explaining the

en

29:14

Why Are Comorbidities Important in Dermatology? Hear...

Derms and Conditions ·

2024/10/03

In this episode of Derms and Conditions, host Dr James Q. Del Rosso welcomes Dr Joel M. Gelfand, Professor of Dermatology and Epidemiology at the University of Pennsylvania, to explore the critical issue of comorbidities in dermatology, with a focus on psoriasis, and address why dermatologists should take an active role in recognizing and addressing these risks.Dr Gelfand reflects on his early observations of patients with psoriasis and their potential internal health issues, noting how in the

en

26:45

How Does TYK2 March To Its Own Drummer?

Derms and Conditions ·

2024/09/19

In this episode of Derms and Conditions, host James Del Rosso, DO, is joined by Jason Hawkes, MD, a dermatologist and investigator at the Medical Research Center of Oregon, to discuss tyrosine kinase 2 (TYK2) inhibitors, particularly deucravacitinib, for plaque psoriasis. They explain how deucravacitinib, which targets the TYK2 pathway, differs from other JAK inhibitors by avoiding the "off-target" effects associated with JAK 1, 2, and 3 inhibitors, offering a more selective and safe treatment

en

151 results

Similar Podcasts

Доктор Тройняшкин

Доктор Тройняшкин

The Dry Eye Treatment PODCAST

Dry Eye Treatment

Différent et alors ?

PATRICK SULAY

Kyle Kingsbury Podcast

Kyle Kingsbury

The Real Weight Loss Coach

Matty Lansdown